Health Care & Life Sciences » Pharmaceuticals | Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2015
2016
2017
2018
Sales/Revenue
-
701.60
1,139.40
1,410.20
Cost of Goods Sold (COGS) incl. D&A
86.80
-
-
-
Gross Income
86.80
-
-
-
SG&A Expense
4,968.40
5,392.80
4,864.70
4,030.50
EBIT
5,055.20
4,863.60
3,912.50
2,808
Non Operating Income/Expense
43.70
2.30
17.80
1
Pretax Income
5,011.40
4,862.80
3,882.40
2,803.70
Income Tax
-
50.70
-
-
Consolidated Net Income
5,011.40
4,812.10
3,882.40
2,803.70
Net Income
5,011.40
4,812.10
3,882.40
2,803.70
Net Income After Extraordinaries
5,011.40
4,812.10
3,882.40
2,803.70
Net Income Available to Common
5,011.40
4,812.10
3,882.40
2,803.70
EPS (Basic)
0.15
0.10
0.06
0.04
Basic Shares Outstanding
34,395.90
47,453.90
67,897.20
75,641.50
EPS (Diluted)
0.15
0.10
0.06
0.04
Diluted Shares Outstanding
34,395.90
47,453.90
67,897.20
75,641.50
EBITDA
4,968.40
4,691.20
3,725.30
2,620.20
Non-Operating Interest Income
-
3.10
12.30
5.30

About Aequus Pharmaceuticals

View Profile
Address
200 Granville Street
Vancouver British Columbia V6C 1S4
Canada
Employees -
Website http://www.aequuspharma.ca
Updated 07/08/2019
Aequus Pharmaceuticals, Inc. focuses on the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.